

EMCDDA activities related to drug related infectious diseases

Roland Simon, Klaudia Palczak, Dagmar Hedrich TT/CSF, Luxembourg, 18.-20. April 2016

Overview

New data and results from

- 1/16: Naloxone report
- 4/16: Drug related acute intoxications/em
- 4/16: EU Drug Markets report

Further activities in 2016

- 5/16: EDR
- 6/16: Hepatitis C treatment for PWID
- EDRR prepared
- Expert meetings
- Drug related deaths projects
- Network development
- Cooperation






Some data and results

Opioids: Opium production increased

FIGURE 4.3
Estimated global illicit opium production and share of Afghanistan, 1995–2014




Sources: UNODC, World Drug Reports.





Opioids: EU market situation



Notes:





Preventing infections, overdoses and deaths


Target population Intervention Increasing awareness and information about overdose risks Retention in **Treatment** treatment as a protective factor Needle and Harm syringe programmes reduction Naloxone programmes Emergency Naloxone administration interventions






Over 50 % of problem opioid users receive treatment

Percentage of problem opioid users receiving substitution treatment (estimate)



Trends in number of clients in OST




NB: Data displayed as point estimates and uncertainty intervals.



emcada.europa.eu

Trends in treatment of opioid problems








HIV diagnoses after harm reduction interventions

New HIV diagnoses among PWID in Greece and Romania, 2004-2014




Source: ECDC/EMCDDA





HIV diagnoses after harm reduction interventions

HIV prevalence among injecting drug users – studies with national and subnational coverage 2013-2014




Source: 2015 EMCDDA Data and Statistics



Hepatitis C: Testing and treatment needed

HCV antibody prevalence among injecting drug users



HCV antibody levels among drug injectors vary between 14 % and 84 %

New diagnostic tools and medications available

High treatment costs are dropping fast

- Samples with national coverage
- Samples with sub-national coverage






emcdda.europa.eu


Drug and deaths

Drug-induced mortality rates among adults

Over 6 100 deaths in 2013

Trends in overdose deaths





emcdda.europa.eu



Further activities in 2016

Major EMCDDA activities in 2016

European Reports

- EDR package 2016: Lisbon launch May 31st
- Drugs Response Report 2017: Preparation

EMCDDA publications

- Insight publication on HCV treatment among PWID
- Rapid communication Infectious diseases and drug harms

Key EMCDDA experts meetings

- June TDI/DRID Expert meeting
- September DRD Expert meeting



Major EMCDDA activities in 2016

Support and collaboration

- with EU-funded projects and Joint Action
- with ECDC, WHO, UNAIDS
- Regional HIV risk assessment, as requested

Topics of special concern


- Chemsex
- Misuse/diversion of substitution substances
- DRD amongst PWID



Overdose deaths

FIGURE 3.1

Age pyramid of drug-induced deaths reported in 2014




Research on reasons for increase in Sweden, Scotland, Denmark end other Member States:

- Age
- Purity
- Shortage
- Misuse





Best Practice Portal: Regular update



THE COCHRANE

COLLABORATION®

EGIONAL OFFICE FOR Europe



emcdda.europa.eu

Major EMCDDA activities in 2016

Working with out networks

- DRID network this year in exchange with TDI network
- Special networks for specific discussions and disseminat

 - Trendspotter

Putting things in perspective

- Illicit substances, NPS and legal substances
- Different viewpoints: therapists, social workers, criminal investigators, toxicologists





